252 related articles for article (PubMed ID: 11165136)
21. ET-743: more than an innovative mechanism of action.
Scotto KW
Anticancer Drugs; 2002 May; 13 Suppl 1():S3-6. PubMed ID: 12173491
[TBL] [Abstract][Full Text] [Related]
22. [Progress in the studies on antitumor natural product ecteinascidin-743].
Wang Y; Liu ZZ; Chen SZ; Liang XT
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):474-8. PubMed ID: 15379280
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.
Li WW; Takahashi N; Jhanwar S; Cordon-Cardo C; Elisseyeff Y; Jimeno J; Faircloth G; Bertino JR
Clin Cancer Res; 2001 Sep; 7(9):2908-11. PubMed ID: 11555609
[TBL] [Abstract][Full Text] [Related]
24. Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.
Marchini S; Marrazzo E; Bonomi R; Chiorino G; Zaffaroni M; Weissbach L; Hornicek FJ; Broggini M; Faircloth GT; D'Incalci M
Eur J Cancer; 2005 Jan; 41(2):323-33. PubMed ID: 15661559
[TBL] [Abstract][Full Text] [Related]
25. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.
García MJ; Saucedo-Cuevas LP; Muñoz-Repeto I; Fernández V; Robles MJ; Domingo S; Palacios J; Aracil M; Nieto A; Tercero JC; Benítez J
Mol Cancer Ther; 2013 Apr; 12(4):530-41. PubMed ID: 23364677
[TBL] [Abstract][Full Text] [Related]
26. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.
Herrero AB; Martín-Castellanos C; Marco E; Gago F; Moreno S
Cancer Res; 2006 Aug; 66(16):8155-62. PubMed ID: 16912194
[TBL] [Abstract][Full Text] [Related]
27. ET-743 (PharmaMar/NCI/Ortho Biotech).
Verschraegen CF; Glover K
Curr Opin Investig Drugs; 2001 Nov; 2(11):1631-8. PubMed ID: 11763168
[TBL] [Abstract][Full Text] [Related]
28. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.
Kanzaki A; Takebayashi Y; Ren XQ; Miyashita H; Mori S; Akiyama S; Pommier Y
Mol Cancer Ther; 2002 Dec; 1(14):1327-34. PubMed ID: 12516966
[TBL] [Abstract][Full Text] [Related]
29. Progress in the development and acquisition of anticancer agents from marine sources.
Amador ML; Jimeno J; Paz-Ares L; Cortes-Funes H; Hidalgo M
Ann Oncol; 2003 Nov; 14(11):1607-15. PubMed ID: 14581267
[No Abstract] [Full Text] [Related]
30. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
[TBL] [Abstract][Full Text] [Related]
31. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
Romano M; Frapolli R; Zangarini M; Bello E; Porcu L; Galmarini CM; García-Fernández LF; Cuevas C; Allavena P; Erba E; D'Incalci M
Int J Cancer; 2013 Nov; 133(9):2024-33. PubMed ID: 23588839
[TBL] [Abstract][Full Text] [Related]
32. Trabectedin: ET 743, ecteinascidin 743, Yondelis.
Drugs R D; 2003; 4(1):75-81. PubMed ID: 12568645
[No Abstract] [Full Text] [Related]
33. Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells.
Acikgoz E; Guven U; Duzagac F; Uslu R; Kara M; Soner BC; Oktem G
PLoS One; 2015; 10(10):e0141090. PubMed ID: 26485709
[TBL] [Abstract][Full Text] [Related]
34. In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects.
Simoens C; Korst AE; De Pooter CM; Lambrechts HA; Pattyn GG; Faircloth GT; Lardon F; Vermorken JB
Br J Cancer; 2003 Dec; 89(12):2305-11. PubMed ID: 14676811
[TBL] [Abstract][Full Text] [Related]
35. Trabectedin mechanism of action: what's new?
D'Incalci M
Future Oncol; 2013 Dec; 9(12 Suppl):5-10. PubMed ID: 24195524
[TBL] [Abstract][Full Text] [Related]
36. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).
Erba E; Bergamaschi D; Bassano L; Ronzoni S; Di Liberti G; Muradore I; Vignati S; Faircloth G; Jimeno J; D'Incalci M
Br J Cancer; 2000 May; 82(10):1732-9. PubMed ID: 10817511
[TBL] [Abstract][Full Text] [Related]
37. New drugs from the sea.
D'Incalci M; Simone M; Tavecchio M; Damia G; Garbi A; Erba E
J Chemother; 2004 Nov; 16 Suppl 4():86-9. PubMed ID: 15688619
[TBL] [Abstract][Full Text] [Related]
38. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
Soares DG; Escargueil AE; Poindessous V; Sarasin A; de Gramont A; Bonatto D; Henriques JA; Larsen AK
Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13062-7. PubMed ID: 17656556
[TBL] [Abstract][Full Text] [Related]
39. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.
Martinez EJ; Owa T; Schreiber SL; Corey EJ
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3496-501. PubMed ID: 10097064
[TBL] [Abstract][Full Text] [Related]
40. Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.
Guirouilh-Barbat J; Antony S; Pommier Y
Mol Cancer Ther; 2009 Jul; 8(7):2007-14. PubMed ID: 19584237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]